Frank Gillardon

Summary

Affiliation: Boehringer Ingelheim

Publications

  1. doi request reprint Leucine-rich repeat kinase 2 phosphorylates brain tubulin-beta isoforms and modulates microtubule stability--a point of convergence in parkinsonian neurodegeneration?
    Frank Gillardon
    Boehringer Ingelheim Pharma GmbH and Co KG, Birkendorfer Str 65, 88397 Biberach an der Riss, Germany
    J Neurochem 110:1514-22. 2009
  2. doi request reprint Interaction of elongation factor 1-alpha with leucine-rich repeat kinase 2 impairs kinase activity and microtubule bundling in vitro
    F Gillardon
    Boehringer Ingelheim Pharma GmbH and Co KG, CNS Research, Birkendorfer St 65, 88397 Biberach an der Riss, Germany
    Neuroscience 163:533-9. 2009
  3. doi request reprint MicroRNA and proteome expression profiling in early-symptomatic α-synuclein(A30P)-transgenic mice
    Frank Gillardon
    Boehringer Ingelheim Pharma GmbH and Co KG, Biberach an der Riss, Germany
    Proteomics Clin Appl 2:697-705. 2008
  4. ncbi request reprint Proteomic and functional alterations in brain mitochondria from Tg2576 mice occur before amyloid plaque deposition
    Frank Gillardon
    Boehringer Ingelheim Pharma GmbH and Co KG, Biberach an der Riss, Germany
    Proteomics 7:605-16. 2007
  5. ncbi request reprint The 20S proteasome isolated from Alzheimer's disease brain shows post-translational modifications but unchanged proteolytic activity
    Frank Gillardon
    Boehringer Ingelheim Pharma GmbH and Co, KG, CNS Research, Biberach an der Riss, Germany
    J Neurochem 101:1483-90. 2007
  6. ncbi request reprint Differential mitochondrial protein expression profiling in neurodegenerative diseases
    Frank Gillardon
    Boehringer Ingelheim Pharma, CNS Research, Biberach, Germany
    Electrophoresis 27:2814-8. 2006
  7. ncbi request reprint Investigating the neuroprotective mechanism of action of a CDK5 inhibitor by phosphoproteome analysis
    Frank Gillardon
    Boehringer Ingelheim Pharma GmbH and Co KG, CNS Research, 88397 Biberach an der Riss, Germany
    J Cell Biochem 95:817-26. 2005
  8. ncbi request reprint Phosphoproteome and transcriptome analysis of the neuronal response to a CDK5 inhibitor
    Frank Gillardon
    Boehringer Ingelheim Pharma GmbH and Co KG, CNS Research, Biberach an der Riss, Germany
    Proteomics 5:1299-307. 2005
  9. doi request reprint Leucine-rich repeat kinase 2 functionally interacts with microtubules and kinase-dependently modulates cell migration
    Mareike Caesar
    Boehringer Ingelheim Pharma GmbH and Co KG, CNS Diseases Research, 88397 Biberach an der Riss, Germany
    Neurobiol Dis 54:280-8. 2013
  10. ncbi request reprint Functional protein kinase arrays reveal inhibition of p-21-activated kinase 4 by alpha-synuclein oligomers
    Karin M Danzer
    Boehringer Ingelheim Pharma GmbH and Co KG, Biberach, Germany
    J Neurochem 103:2401-7. 2007

Collaborators

Detail Information

Publications17

  1. doi request reprint Leucine-rich repeat kinase 2 phosphorylates brain tubulin-beta isoforms and modulates microtubule stability--a point of convergence in parkinsonian neurodegeneration?
    Frank Gillardon
    Boehringer Ingelheim Pharma GmbH and Co KG, Birkendorfer Str 65, 88397 Biberach an der Riss, Germany
    J Neurochem 110:1514-22. 2009
    ..These findings suggest that LRRK2(G2019S)-induced neurodegeneration in Parkinsonian brains may be partly mediated by increased phosphorylation of tubulin-beta and constraining of microtubule dynamics...
  2. doi request reprint Interaction of elongation factor 1-alpha with leucine-rich repeat kinase 2 impairs kinase activity and microtubule bundling in vitro
    F Gillardon
    Boehringer Ingelheim Pharma GmbH and Co KG, CNS Research, Birkendorfer St 65, 88397 Biberach an der Riss, Germany
    Neuroscience 163:533-9. 2009
    ..These findings suggest that the interaction between LRRK2 and EF1A may reciprocally modulate their physiological function...
  3. doi request reprint MicroRNA and proteome expression profiling in early-symptomatic α-synuclein(A30P)-transgenic mice
    Frank Gillardon
    Boehringer Ingelheim Pharma GmbH and Co KG, Biberach an der Riss, Germany
    Proteomics Clin Appl 2:697-705. 2008
    ..MicroRNA may thus represent novel biomarkers for neuronal malfunction and potential therapeutic targets for human neurodegenerative diseases...
  4. ncbi request reprint Proteomic and functional alterations in brain mitochondria from Tg2576 mice occur before amyloid plaque deposition
    Frank Gillardon
    Boehringer Ingelheim Pharma GmbH and Co KG, Biberach an der Riss, Germany
    Proteomics 7:605-16. 2007
    ..Taken together, we demonstrate alterations in the mitochondrial proteome and function that occur in Tg2576 mice brains before amyloid plaque deposition suggesting that mitochondria are early targets of amyloid-beta aggregates...
  5. ncbi request reprint The 20S proteasome isolated from Alzheimer's disease brain shows post-translational modifications but unchanged proteolytic activity
    Frank Gillardon
    Boehringer Ingelheim Pharma GmbH and Co, KG, CNS Research, Biberach an der Riss, Germany
    J Neurochem 101:1483-90. 2007
    ..Post-translational modifications of non-catalytic subunits in situ may contribute to the trend towards enhanced hydrolytic activity of the isolated 20S proteasome after removal of the endogenous inhibitors...
  6. ncbi request reprint Differential mitochondrial protein expression profiling in neurodegenerative diseases
    Frank Gillardon
    Boehringer Ingelheim Pharma, CNS Research, Biberach, Germany
    Electrophoresis 27:2814-8. 2006
    ..The main emphasis is put on gel-based proteomic approaches to identify differentially expressed mitochondrial proteins in neurodegenerative diseases...
  7. ncbi request reprint Investigating the neuroprotective mechanism of action of a CDK5 inhibitor by phosphoproteome analysis
    Frank Gillardon
    Boehringer Ingelheim Pharma GmbH and Co KG, CNS Research, 88397 Biberach an der Riss, Germany
    J Cell Biochem 95:817-26. 2005
    ..These results suggest that inhibition of CDK5 activates stress responsive proteins that may protect neurons against subsequent injurious stimuli...
  8. ncbi request reprint Phosphoproteome and transcriptome analysis of the neuronal response to a CDK5 inhibitor
    Frank Gillardon
    Boehringer Ingelheim Pharma GmbH and Co KG, CNS Research, Biberach an der Riss, Germany
    Proteomics 5:1299-307. 2005
    ..Taken together, phosphoproteome and transcriptome analysis indicate that the compound promotes both neuronal survival and neurite outgrowth, but also may affect synaptic function in cultured neurons...
  9. doi request reprint Leucine-rich repeat kinase 2 functionally interacts with microtubules and kinase-dependently modulates cell migration
    Mareike Caesar
    Boehringer Ingelheim Pharma GmbH and Co KG, CNS Diseases Research, 88397 Biberach an der Riss, Germany
    Neurobiol Dis 54:280-8. 2013
    ..These findings suggest that LRRK2 and microtubules mutually interact both in non-neuronal cells and in neurons, which might contribute to our understanding of its pathogenic effects in Parkinson's disease...
  10. ncbi request reprint Functional protein kinase arrays reveal inhibition of p-21-activated kinase 4 by alpha-synuclein oligomers
    Karin M Danzer
    Boehringer Ingelheim Pharma GmbH and Co KG, Biberach, Germany
    J Neurochem 103:2401-7. 2007
    ..Thus, PAKs may represent a target for various neurotoxic protein oligomers, and signaling deficits may contribute to the behavioral defects in chronic neurodegenerative diseases...
  11. doi request reprint ATP-competitive LRRK2 inhibitors interfere with monoclonal antibody binding to the kinase domain of LRRK2 under native conditions. A method to directly monitor the active conformation of LRRK2?
    Frank Gillardon
    CNS Research, Boehringer Ingelheim Pharma GmbH and Co KG, Biberach an der Riss, Germany
    J Neurosci Methods 214:62-8. 2013
    ..Since kinase inhibitors prevent autophosphorylation and refolding of the activation segment, we hypothesize that the antibody preferentially binds to the active conformation of LRRK2 under native conditions...
  12. pmc Signal transduction protein array analysis links LRRK2 to Ste20 kinases and PKC zeta that modulate neuronal plasticity
    Susanne Zach
    Boehringer Ingelheim Pharma GmbH and Co KG, CNS Research, Biberach an der Riss, Germany
    PLoS ONE 5:e13191. 2010
    ..LRRK2 has been linked to the mitogen-activated protein kinase kinase kinase family and the receptor-interacting protein kinases based on sequence similarity within the kinase domain and in vitro substrate phosphorylation...
  13. pmc Leucine-rich repeat kinase 2 modulates retinoic acid-induced neuronal differentiation of murine embryonic stem cells
    Cathrin Schulz
    Boehringer Ingelheim Pharma GmbH and Co KG, CNS Research, Biberach an der Riss, Germany
    PLoS ONE 6:e20820. 2011
    ..LRRK2 is expressed in neural precursor cells suggesting a role in neurodevelopment...
  14. doi request reprint Identification of novel substrates for Cdk5 and new targets for Cdk5 inhibitors using high-density protein microarrays
    Cathrin Schnack
    Boehringer Ingelheim Pharma GmbH and Co KG, CNS Research, Biberach an der Riss, Germany
    Proteomics 8:1980-6. 2008
    ..However, several false negative results possibly due to a denatured or inactive conformation of the arrayed proteins, sound a note of caution when using protein array techniques...
  15. doi request reprint Activation of the mitochondrial protein quality control system and actin cytoskeletal alterations in cells harbouring the MELAS mitochondrial DNA mutation
    Sandra Felk
    Boehringer Ingelheim Pharma GmbH and Co KG, Biberach an der Riss, Germany
    J Neurol Sci 295:46-52. 2010
    ..These findings provide novel insights into the cellular response to dysfunctional mitochondria containing mutated genomes...
  16. ncbi request reprint Inhibition of CDK5 is protective in necrotic and apoptotic paradigms of neuronal cell death and prevents mitochondrial dysfunction
    Jochen H Weishaupt
    Department of Neurology, University Hospital Gottingen, Robert Koch Strasse 40, 37075 Gottingen, Germany
    Mol Cell Neurosci 24:489-502. 2003
    ..Moreover, we present the first CDK5-selective small molecule inhibitor, lacking unwanted cytostatic effects due to cross-inhibition of mitotic CDKs...
  17. ncbi request reprint Regulation of protein phosphatase inhibitor-1 by cyclin-dependent kinase 5
    Chan Nguyen
    Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA
    J Biol Chem 282:16511-20. 2007
    ..Thus, inhibitor-1 serves as a critical junction between kinase- and phosphatase-signaling pathways, linking PP-1 to not only PKA and calcineurin but also Cdk5...